Bibliography
- Liow K, Barkley GL, Pollard JR, et al. American Academy of Neurology. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007;68:1249-50
- AMCP board of directors, where we stand on generic drugs. Available from: http://www.amcp.org/amcp.ark?p=AA2D6237. [Accessed 16 April 2009]
- US Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations (Orange Book), 28th edition. 2008. Available from: http://www.fda.gov/cder/orange/obannual.pdf. [Accessed 2 December 2008]
- Berg M. What's the problem with generic antiepileptic drugs? A call to action. Neurology 2007;68:1245-6
- Feely M, Crawford P, Krämer G, Guberman A. Risk management in epilepsy: generic substitution and continuity of supply. Eur J Hospital Pharm Sci 2005;11(4):83-7
- Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 2006;15(3):165-76
- LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Contemporary issues in neurologic practice. Neurology 2008;70:2179-86
- Kramer G, Biraben A, Carreno M, et al. Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav 2007;11:46-52
- Berkovic SF. Treatment with anti-epileptic drugs. Aust Fam Physician 2005;34:1017-20
- “Prescription Drug Trends”, Kaiser family foundation prescription drugs trends fact sheet, September, 2008: p. 1. Available from: http://www.kff.org/rxdrugs/3057.cfm. [Accessed 11 December 2008]
- Catlin A, Cowan C, Hartman M, Heffler S, and the National Health Expenditure Accounts Team. National Health Spending in 2006: a year of change for prescription drugs. Health Aff 2008;27(1):14-29
- Express Scripts, 2007 Drug Trend Report, April 2008:p. 3. Available from: http://www.express-scripts.com/industryresearch/industryreports/. [Accessed 11 December 2008]
- Medco, Drug Trend Report, 2007;9:8-10. Available from: http://medco.mediaroom.com/index.php?s=64&cat=5. [Accessed 11 December 2008]
- Grabowski H. Competition between generic and branded drugs. chapter 8. In: Sloan FA, Hsieh CR, editor, Pharmaceutical innovation. New York, NY: Cambridge Press, 2007: p. 154, 158
- LeLorier J, Duh MS, Paradis PE, et al. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. Curr Med Res Opin 2008;24(4):1069-81
- Papsdorf T, Ablah E, Ram S, et al. Patient perception of generic antiepileptic drugs in the Midwestern United States. Epilepsy Behav 2008. In press
- American Medical Association. Generic substitution of narrow therapeutic index drugs. Available from: http://www.ama-assn.org/ama/pub/category/17731.html. [Accessed on 24 December 2008]
- Privitera MD. Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr 2008;8(5):113-7
- Greenberg P. Does generic substitution always make sense? J Med Econ 2008;11:547-53
- Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25(6):1578-92
- Guberman A, Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci 2000;27:37-43
- Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 2004;5:995-8
- Meredith PA. Generic drugs: therapeutic equivalence. Drug Saf 1996;15:233-42
- Meredith P. Bioequivalence and other unresolved issues in generic substitution. Clin Ther 2003;25:2875-90
- Begley CE, Beghi E. The economic cost of epilepsy: a review of the literature. Epilepsia 2002;43(4):3-9
- EUCARE, Brodie MJ, deBoer HM, Johannessen SI (eds.). European white paper on epilepsy. Epilepsia 2003;44 (Suppl 6):1-88
- Banahan BF, Bonnarens JK, Bentley JP. Generic substitution of NTI drugs: issues for formulary committee consideration. Formulary 1998;33:1082-96
- Benet LZ, Goyan JE. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy 1995;15:433-40
- Sander JW. The use of antiepileptic drugs – principles and practice. Epilepsia 2004;45(6):28-34
- Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs 2006;66(14):1817-29
- Yeager KA, DiIorio C, Shafer PO, et al. The complexity of treatments for persons with epilepsy. Epilepsy Behav 2005;7:679-86
- Lamy PP. Generic equivalents: issues and concerns. J Clin Pharmacol 1986;26:30916
- Besag FM. Is generic prescribing acceptable in epilepsy? Drug Saf 2000;23(3):173-82
- Tompson DJ, Ali I, Oliver-Willwong R. Steady-state pharmacokinetics of lamotrigine when converting fromat wice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (the COMPASS study). Epilepsia 2008;49:410-17
- Leppik IE. Epilepsy in the elderly. Epilepsia 2006;47(Suppl 1):65-70
- Anonymous. For and against generic prescribing. Drug Ther Bull 1987;25:93-5
- Sachdeo RC, Belendiuk G. Generic versus branded carbamazepine. Lancet 1987;I:1432
- Jumoa-as A, Bella I, Craig B, et al. Comparison of steady state blood levels of two carbamazepine formulations. Epilepsia 1989;30:67-70
- Gilman JT, Alvarez LA, Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology 1993;(43):2696-97
- Vadney VJ, Kraushaar KW. Effects of switching from depakenetogeneric valproic acid on individuals with mental retardation. Ment Retard 1997;35:468-72
- Jobst BC, Holmes GL. Prescribing antiepileptic drugs: should patients be switched on the basis of cost? CNS Drugs 2004;18:617-28
- Duh MS, Andermann F, Paradis PE, et al. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Dis Manag 2007;10(4):216-25
- Duh MS, Paradis PE, Latrémouille-Viau D, et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 2009. In press
- Paradis PE, Latrémouille-Viau D, Moore Y, et al. Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. 2009, manuscript in preparation
- Helmers S, Paradis PE, Manjunath R, et al. The direct health care cost burden associated with the use of generic antiepileptic drugs in the United States, manuscript in preparation
- Murray MI, Halpern MT, Leppik IE. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996;23:139-48
- Berg MJ, Gross RA, Haskins LS, et al. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav 2008;13:693-9
- EmedTV. Available from: http://epilepsy.emedtv.com. [Accessed 19 December 2008]
- Epilepsy.com. Available from: http://epilepsy.com/epilepsy/history. [Accessed 19 December 2008]
- Heaney D, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol 2007;6:465-8
- International AED name database. Available from: http://www.ilae.org/visitors/centre/aeds/epilepsy. [Accessed 19 December 2008]
- RxNews. Primary patent expirations for selected high revenue drugs. Available from: http://www.prescriptionsolutions.com/c/rxnews/rxnews_view.asp?Article=674&type=19. [Accessed 19 December 2008]
- Argumosa A, Herranz JL. The clinical and economic impact of generic drugs in the treatment of epilepsy. Rev Neurol 2005;41:45-9